Despite having robust biologic activities to promote anti-tumor immunity, the therapeutic use of native cytokines is hindered by their systemic toxicity. The ATAC platform is designed to fuse attenuated cytokines (muteins) to antibodies targeting cancer enriched antigens to restore the intrinsic activity of the cytokine upon targeted delivery to the tumor microenvironment (TME) while avoiding the systemic toxicity of the native cytokine. Our ATAC candidates are unique in possessing both cis- and trans- activities simultaneously targeting both tumor cells by inducing apoptosis/growth inhibition and immune cells (T-cells, NK-cells and dendritic cells) by activating and enhancing effector function within the TME. Despite the attenuated activity of the cytokines, the delivery to the tumor creates a localization effect which enhances the activity significantly in the local environment.
REMD has 2 programs in advanced pre-clinical development using this technology.